Jacobson Pharma Corporation Limited (HK:2633)
:2633
Want to see HK:2633 full AI Analyst Report?
2633 Stock Chart & Stats
HK$1.29
HK$0.01(0.99%)
At close: 4:00 PM EST
HK$1.29
HK$0.01(0.99%)
Day’s Range― - ―
52-Week RangeHK$1.11 - HK$1.78
Previous CloseN/A
Volume1.98M
Average Volume (3M)821.71K
Market Cap
HK$2.17B
Enterprise ValueHK$2.77B
Total Cash (Recent Filing)HK$395.06M
Total Debt (Recent Filing)HK$904.62M
Price to Earnings (P/E)5.1
Beta0.06
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield15.4%
Share Statistics
EPS (TTM)0.07
Shares Outstanding2,000,221,000
10 Day Avg. Volume1,775,382
30 Day Avg. Volume821,706
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.96
Price to Sales (P/S)1.49
P/FCF Ratio8.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$2.45Price Target Upside89.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.16
Revenue Forecast (FY)HK$1.65B
Bulls Say, Bears Say
Bulls Say
Strong Operating & Free Cash FlowConsistent strong operating cash flow and growing free cash flow provide durable internal funding for R&D, capex, dividends and debt reduction. Reliable cash generation enhances resilience through cycles, supports strategic investments and preserves financial flexibility over the next several quarters.
Healthy Margins And ProfitabilitySustained healthy gross and operating margins indicate persistent pricing power and effective cost controls in core pharma operations. Margin durability supports reinvestment and cash flow conversion, insulating long-term profitability from moderate revenue fluctuations and competitive pressures.
Solid Equity Base And Favorable ROEA strong equity base and favorable ROE signal efficient capital allocation and a sturdy financial foundation. Manageable leverage alongside solid equity increases capacity for M&A, product development and capital returns while reducing solvency risk across multi-quarter horizons.
Bears Say
Recent Slight Revenue DeclineA recent decline in reported revenue, albeit modest, raises questions about product mix, market saturation or demand softness. If the trend persists it could constrain margin expansion, limit reinvestment and challenge long-term growth targets unless offset by new products or market expansion.
Moderate Leverage Needs MonitoringModerate leverage reduces financial flexibility and raises interest and refinancing risk over time. If cash needs rise or margins compress, servicing debt could constrain capex and strategic spending, making leverage a structural risk to preserve capital allocation optionality.
Limited Investor Communication / Earnings DetailAbsence of detailed earnings call disclosures and guidance limits visibility into management’s forward strategy and execution risks. Reduced transparency complicates long-term assessment of pipeline progress, commercialization plans and management accountability for multi-quarter planning.
Jacobson Pharma Corporation Limited News
2633 FAQ
What was Jacobson Pharma Corporation Limited’s price range in the past 12 months?
Jacobson Pharma Corporation Limited lowest stock price was HK$1.11 and its highest was HK$1.78 in the past 12 months.
What is Jacobson Pharma Corporation Limited’s market cap?
Jacobson Pharma Corporation Limited’s market cap is HK$2.17B.
When is Jacobson Pharma Corporation Limited’s upcoming earnings report date?
Jacobson Pharma Corporation Limited’s upcoming earnings report date is Jul 01, 2026 which is in 63 days.
How were Jacobson Pharma Corporation Limited’s earnings last quarter?
Jacobson Pharma Corporation Limited released its earnings results on Nov 18, 2025. The company reported HK$0.071 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.071.
Is Jacobson Pharma Corporation Limited overvalued?
According to Wall Street analysts Jacobson Pharma Corporation Limited’s price is currently Undervalued.
Does Jacobson Pharma Corporation Limited pay dividends?
Jacobson Pharma Corporation Limited pays a Semiannually dividend of HK$0.043 which represents an annual dividend yield of 15.4%. See more information on Jacobson Pharma Corporation Limited dividends here
What is Jacobson Pharma Corporation Limited’s EPS estimate?
Jacobson Pharma Corporation Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jacobson Pharma Corporation Limited have?
Jacobson Pharma Corporation Limited has 2,000,221,000 shares outstanding.
What happened to Jacobson Pharma Corporation Limited’s price movement after its last earnings report?
Jacobson Pharma Corporation Limited reported an EPS of HK$0.071 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.418%.
Which hedge fund is a major shareholder of Jacobson Pharma Corporation Limited?
Currently, no hedge funds are holding shares in HK:2633
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jacobson Pharma Corporation Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.83%
12-Months-Change
Fundamentals
Return on Equity
12.91%
Trailing 12-Months
Asset Growth
-2.19%
Trailing 12-Months
Company Description
Jacobson Pharma Corporation Limited
Jacobson Pharma Corporation Limited, through its subsidiaries, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including the respiratory, cardiovascular, central nervous system, gastrointestinal, genito-urinary, musculoskeletal, endocrine and metabolic, dermatological, anti-allergics, scar treatment, oral anti-diabetics, and anti-infective, as well as arsenic trioxide oral solutions, rosuvastatin tablets, and atorvastatin tablets. It also provides branded medicines; health and wellness products; and proprietary Chinese medicines, such as Po Chai pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling oil, Contractubex, Doan's Ointment, and Col-gan tablets. In addition, it engages in the trading of medical supplies; procurement of packaging materials; sale of healthcare and herbal products; research and development; and property holding activities. Jacobson Pharma Corporation Limited sells its products to hospitals and clinics, and registered pharmacies, as well as to doctors in private and retail outlets, and trading companies. The company was incorporated in 2016 and is headquartered in Kwun Tong, Hong Kong. Jacobson Pharma Corporation Limited is a subsidiary of Kingshill Development Limited.
2633 Stock 12 Month Forecast
Average Price Target
HK$2.45
▲(89.92% Upside)
Technical Analysis
Lee's Pharmaceutical Holdings Limited
―
JBM (Healthcare) Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
China Shineway Pharmaceutical Group Limited
―
Golden Throat Holdings Group Co Ltd
―
Options Prices
Currently, No data available
---